Medical/Pharmaceuticals
Harnessing Generative AI in Healthcare and Improving Cardiometabolic Health with Precision Medicine: Key Opportunities and Insights
HOUSTON, Oct. 22, 2024 /PRNewswire/ -- In today's rapidly evolving healthcare landscape, two powerful forces are reshaping how we diagnose, treat, and manage health conditions: Generative artificial intelligence (GenAI) and precision medicine for cardiometabolic health. GenAI promises to revoluti...
2024-10-22 22:51
1293
Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
MELBOURNE, Australia, Oct. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the spin-off of Rhine Pharma[1], which has the mission of expanding global access to innovative radiopharmaceuticals for cancer imaging and treatment using two gen...
2024-10-22 18:57
1656
Minghui Pharmaceutical Inc. Announces Positive Topline Results from Phase Ib/II Clinical Trial of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Patients with Active, Moderate-to-Severe Thyroid Eye Disease (TED)
SHANGHAI, Oct. 22, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced positive topline results from its Phase Ib/II clinical trial of MHB018A in patients with active...
2024-10-22 18:00
4658
World Psoriasis Day 2024: Psoriatic Disease and Family--Standing Together in Support and Understanding
STOCKHOLM, Oct. 22, 2024 /PRNewswire/ -- Each year on October 29th, the global community unites on World Psoriasis Day to raise awareness and advocate for progress in the fight against psoriatic disease. This year, the focus is on the profound impact of psoriatic disease on families, highlighted ...
2024-10-22 16:00
2135
HELP Therapeutics announces FDA clearance of IND application for universal iPSC-derived HiCM-188 cell therapy for the treatment of end-stage heart failure
NANJING, China, Oct. 22, 2024 /PRNewswire/ -- HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company,today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for "Allogeneic Human iPSC-derived cardiomyocytes (HiCM-188) a...
2024-10-22 13:47
1007
South Korean Mental Tech Startup DoctorPresso Publishes Study to Detect Depression from User-Generated Diary test data in International Journal
SEOUL, South Korea, Oct. 21, 2024 /PRNewswire/ -- Doctorpresso's study to detect depression from user-generated diary text data was published in the September 2024 issue of the Journal of Medical Internet Research (JMIR) in recognition of its excellence. JMIR noted the "new approach of Doctorpress...
2024-10-22 09:08
1788
Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON® Global Phase 3 NefIgArd Clinical Trial Published in "Kidney 360" Magazine
SHANGHAI, Oct. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the "Kidney 360" magazine has pu...
2024-10-22 07:40
1738
A Comprehensive Introduction of the oneClick+ antigen platform
SHANGHAI, Oct. 21, 2024 /PRNewswire/ -- Sanyou Bio provides oneClick+ antigen one-stop solution, from antigen analysis to personalized preparation, to help tumor immunotherapy research and development. oneClick+ antigen platform is designed to provide high-quality annotation-related protein seque...
2024-10-22 03:00
1250
Moleac Announces PT Ferron Par Pharmaceuticals as New Exclusive Partner in Indonesia
SINGAPORE, Oct. 21, 2024 /PRNewswire/ -- Moleac is excited to announce a significant milestone in the journey of NeuroAiD II MLC901 asPT Ferron Par Pharmaceuticalswill become our exclusive partner in Indonesia effective Jan 1st 2025. We are immensely grateful for the fruitful 12-year partnership...
2024-10-21 22:20
1762
Datasea Announces the Closing of a $4.0 Million Private Offering, Primarily Funded by the Company's CEO and Director
BEIJING, Oct. 21, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based digital technology company focused on innovative high-tech acoustics and 5G AI multimodal digital technology, today announced that, as ofOctober 15, 2024, the Company closed its Regulati...
2024-10-21 21:30
2340
Mediso introduces true theranostic TheraMAX SPECT/CT
HAMBURG, Germany, Oct. 21, 2024 /PRNewswire/ -- Mediso is unveiling its new
AnyScan® TRIO SPECT/CT, TheraMAX* scanner at the annual meeting of European
Association of Nuclear Medicine (EANM).
2024-10-21 16:00
1020
Great Bay Bio Intelligent Drug Development Ecosystem Officially Launched
HONG KONG, Oct. 20, 2024 /PRNewswire/ -- On October 18th, the new product launch event hosted by Great Bay Bio (hereinafter referred to as "GBB") was successfully held in Suzhou, where industry players gathered to celebrate the feast of technological innovation. At the event, GBB announced the of...
2024-10-21 13:57
1015
Chang Gung Memorial Hospital Unveils Cellular Therapy: A Beacon of Hope for Cancer Treatment
Cellular Therapy Emerges as a Front-Runner in Medical Innovation TAOYUAN, Oct. 21, 2024 /PRNewswire/ -- Cellular therapy, a revolutionary approach where cells are manipulated outside the body and then reintroduced to treat or prevent diseases, has been recognized in recent years as a highly prom...
2024-10-21 09:03
3629
Everest Medicines Announces Taiwan TFDA Approval of NEFECON® for the Treatment of Primary IgA Nephropathy
SHANGHAI , Oct. 21, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announces that the Taiwan Food and Drug Admini...
2024-10-21 07:40
1703
Humavant® 100% Human Milk-Based Fortifiers Helping Premature Infants in Australia Grow and Develop
Human Milk-Based Nutrition Is Clinically Demonstrated to Improve Health Outcomes in Very Low Birth Weight Babies Compared to Cow Milk-Based Products ADELAIDE, Australia, Oct. 21, 2024 /PRNewswire/ -- Prolacta Bioscience®, the world's leading hospital provider of 100% human milk-based nutritional ...
2024-10-21 04:05
1717
Hong Kong Breast Cancer Foundation "Pink Walk 2024" Charity Walk Concluded Successfully
Nearly 2,000 Pink Walkers gathered at The Peak Walk for Breast Health, Together We Can HONG KONG, Oct. 20, 2024 /PRNewswire/ -- The signature annual charity walk, "Pink Walk 2024", organised by Hong Kong Breast Cancer Foundation (HKBCF), was successfully held today at The Peak,Hong Kong Island. ...
2024-10-20 17:23
2044
Curio Digital Therapeutics Applauded by Frost & Sullivan for Enhancing Women's Maternal Mental Healthcare with its MamaLift and MamaLift Plus Solutions
MamaLift ensures personalized care tailored to each woman's journey through motherhood, empowering them to manage stress, embrace joy, and reduce the risk of depression and anxiety during and after pregnancy. SAN ANTONIO, Oct. 19, 2024 /PRNewswire/ -- Frost & Sullivan assessed the women's health...
2024-10-19 23:30
2167
MicuRx Pharmaceuticals Showcases the Pipeline Status of MRX-5 and MRX-8 at BIO Investor Forum
SAN FRANCISCO, Oct. 18, 2024 /PRNewswire/ -- Dr. Regis Vilchez, Chief Medical Officer of MicuRx Pharmaceuticals, presented the latest advancements of company's development program, MRX-5 and MRX-8, at the BIO Investor Forum (BIF). These development programs offer new potentials for the future tre...
2024-10-18 22:09
1282
Neurophet to host Symposium featuring renowned expert in Alzheimer's disease treatment from the U.S.
- Invited Neurophet's scientific advisor Stephen Salloway, professor of Neurology at Brown Medical School as guest speaker - Shared latest insights on brain image analysis used for prescription of Alzheimer's disease treatments such as 'Leqembi' and 'Kisunla' SEOUL, South Korea, Oct. 18, 2024 /P...
2024-10-18 21:00
2560
LaNova Medicines Announces Initiation of Phase 1 Clinical Trial of Anti-PD-1/VEGF Bispecific Antibody LM-299 and Completion of $42 Million Series C1 Financing
* Phase 1 trial of LM-299, an anti-PD-1/VEGF BsAb, initiated in China for advanced solid tumors following promising preclinical results demonstrating strong inhibition of tumor growth and well-tolerated safety profile * IND for LM-299 in the US expected to be submitted in the second half of 20...
2024-10-18 18:00
1440
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 312 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8700
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5793
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5179
